Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations

被引:58
作者
Boettcher, Sebastian [1 ]
Ritgen, Matthias [1 ]
Buske, Sebastian [1 ]
Gesk, Stefan [2 ]
Klapper, Wolfram [3 ,4 ]
Hoster, Eva [5 ]
Hiddemann, Wolfgang [5 ]
Unterhalt, Michael [5 ]
Dreyling, Martin [5 ]
Siebert, Reiner [2 ]
Kneba, Michael [1 ]
Pott, Christiane [1 ]
机构
[1] Univ Schleswig Holstein, Dept Med 2, Kiel, Germany
[2] Univ Schleswig Holstein, Inst Human Genet, Kiel, Germany
[3] Univ Schleswig Holstein, Dept Haematopathol, Kiel, Germany
[4] Univ Schleswig Holstein, Lymph Node Registry Kiel, Kiel, Germany
[5] Univ Munich, Hosp Grosshadern, Dept Internal Med 3, Munich, Germany
关键词
mantle cell lymphoma; flow cytometry; PCR; staging; minimal residual disease;
D O I
10.3324/haematol.11267
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The increasing application of multi-color flow cytometry assays for staging and follow-up in mantle cell lymphoma necessitates that the specificity and sensitivity of this technique are evaluated. Data from prospective clinical trials comparing the clinical applicability of flow cytometry to routine diagnostic methods and to polymerase chain reaction are currently lacking. Design and Methods We applied a standardized four-color flow cytometry assay to 281 prospectively collected peripheral blood and bone marrow samples from 98 patients with mantle cell lymphoma participating in a multi-center clinical trial and compared the results to those obtained with conventional clinical staging and consensus primer IGH-polymerase chain reaction. Results The maximum sensitivity of flow cytometry using light chain restriction in CD19'CD5' sub-populations was 8.0x10(-4) while flow cytometry that relied on immunophenotypic aberrations was less sensitive (2.4x10(-3)). Mantle cell lymphoma cells were detected in 87.3% of 110 pre-treatment samples from 84 patients by flow cytometry and in 94.5% by polymerase chain reaction. Eight out of 84 patients (9.5%) diagnosed clinically as having stage II or III disease showed peripheral blood or bone marrow involvement according to flow cytometry, thus documenting more advanced disease. At follow-up residual lymphoma cells were detected by flow cytometry and concordantly by polymerase chain reaction in 10/171 samples (5.8%); however, 31 follow-up samples (18.1%) were positive for minimal residual disease according only to polymerase chain reaction analysis. Conclusions The sensitivity of four-color flow cytometry is comparable to that of IGH-polymerase chain reaction at initial staging but is less sensitive at follow-up after immuno-chemotherapy. Both techniques are highly valuable methods for accurate initial staging.
引用
收藏
页码:551 / 559
页数:9
相关论文
共 51 条
  • [21] Evaluation of peripheral blood involvement of mantle cell lymphoma by fluorescence in situ hybridization in comparison with immunophenotypic and morphologic findings
    Gu, J
    Huh, YO
    Jiang, F
    Caraway, NP
    Romaguera, JE
    Zaidi, TM
    Fernandez, RL
    Zhang, HZ
    Khouri, IF
    Katz, RL
    [J]. MODERN PATHOLOGY, 2004, 17 (05) : 553 - 560
  • [22] Immunophenotypic analysis of peripheral blood and bone marrow in the staging of B-cell malignant lymphoma
    Hanson, CA
    Kurtin, PJ
    Katzmann, JA
    Hoyer, JD
    Li, CY
    Hodnefield, JM
    Meyers, CH
    Habermann, TM
    Witzig, TE
    [J]. BLOOD, 1999, 94 (11) : 3889 - 3896
  • [23] Flow cytometric analysis of BCL-2 can distinguish small numbers of acute lymphoblastic leukaemia cells from B-cell precursors
    Hartung, L
    Bahler, DW
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2004, 127 (01) : 50 - 58
  • [24] Hoffkes H, 1995, Eur J Med Res, V1, P2
  • [25] Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival
    Howard, OM
    Gribben, JG
    Neuberg, DS
    Grossbard, M
    Poor, C
    Janicek, MJ
    Shipp, MA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) : 1288 - 1294
  • [26] CD58 expression decreases as nonmalignant B cells mature in bone marrow and is frequently overexpressed in adult and pediatric precursor B-cell acute lymphoblastic leukemia
    Lee, RV
    Braylan, RC
    Rimsza, LM
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2005, 123 (01) : 119 - 124
  • [27] Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma:: a prospective study
    Lefrère, F
    Delmer, A
    Suzan, F
    Levy, V
    Belanger, C
    Djabarri, M
    Arnulf, B
    Damaj, G
    Maillard, N
    Ribrag, V
    Janvier, M
    Sebban, C
    Casasnovas, RO
    Bouabdallah, R
    Dreyfus, F
    Verkarre, V
    Delabesse, E
    Valensi, F
    McIntyre, E
    Brousse, N
    Varet, B
    Hermine, O
    [J]. LEUKEMIA, 2002, 16 (04) : 587 - 593
  • [28] Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma:: Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG)
    Lenz, G
    Dreyling, M
    Hoster, E
    Wörmann, B
    Dührsen, U
    Metzner, B
    Eimermacher, H
    Neubauer, A
    Wandt, H
    Steinhauer, H
    Martin, S
    Heidemann, E
    Aldaoud, A
    Parwaresch, R
    Hasford, J
    Unterhalt, M
    Hiddemann, W
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) : 1984 - 1992
  • [29] Automated high resolution PCR fragment analysis for identification of clonally rearranged immunoglobulin heavy chain genes
    Linke, B
    Bolz, I
    Fayyazi, A
    vonHofen, M
    Pott, C
    Bertram, J
    Hiddemann, W
    Kneba, M
    [J]. LEUKEMIA, 1997, 11 (07) : 1055 - 1062
  • [30] Liu Z, 2002, AM J CLIN PATHOL, V118, P216